Gynesonics, a women’s healthcare medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, has announced CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency. This new initiative is with the support of the American College of Obstetrics and Gynecology (ACOG), where the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code, 58580, for transcervical uterine fibroid(s) ablation with ultrasound guidance using radiofrequency.
The AMA CPT Editorial Panel has agreed that this service meets the criteria for a Category I assignment based on the procedure being consistent with current medical practice, and where the clinical efficacy of the procedure is documented in literature that meets the AMA CPT requirements. The new code is effective from January 1, 2024.
Medical practitioners use CPT codes to report healthcare services. This standardized nationwide identification system provides a uniform language for reporting medical services and has been used by Medicare, Medicaid, and Commercial plans for over half a century.
Commenting on the new CPT code, Skip Baldino, President and Chief Executive Officer of Gynesonics said, “We are very pleased that the AMA has established a new Category I code that applies to our Sonata Procedure for the treatment of uterine fibroids. This unique code will simplify the process for providers and insurers of submitting and processing claims on behalf of their patients. The code is a critical milestone for the broader adoption of the technology to treat uterine fibroids in the United States. We sincerely appreciate the efforts of the AMA and the CPT Editorial Panel to establish a Category 1 code, acknowledging the innovation and efficacy of the Sonata transcervical fibroid ablation.”
Uterine fibroids are benign masses in or around the uterus. They are common and most women develop them during childbearing age. Symptoms of fibroids include abnormal uterine bleeding, abdominal pelvic pain or pressure, increased abdominal girth, urinary frequency, constipation, preterm labor, and painful intercourse.
The Sonata System is a technology platform that integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Procedure is a breakthrough alternative to hysterectomy and myomectomy and can treat a wide range of fibroid types, sizes, and locations. Fibroids are treated from inside the uterus, so the Sonata Procedure requires no incisions, no tissue is surgically removed, and the uterus is preserved.
Click here to learn more about Gynesonics.
